stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Current ratio
Alnylam Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 2.5×, down 0.3× from fiscal 2025 (2.8×). Over the past ten years it has ranged from 2.8× (fiscal 2025) to 17.8× (fiscal 2015) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.8× | (0.55%) |
| FY2024 | 2.8× | (9.87%) |
| FY2023 | 3.1× | (12.09%) |
| FY2022 | 3.5× | (13.16%) |
| FY2021 | 4.0× | (9.64%) |
| FY2020 | 4.5× | (8.19%) |
| FY2019 | 4.9× | (27.25%) |
| FY2018 | 6.7× | (45.32%) |
| FY2017 | 12.2× | 139.80% |
| FY2016 | 5.1× | (71.34%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.5× | (18.87%) |
| Jun 2026 | 3.1× | (2.30%) |
| Mar 2026 | 3.1× | 13.18% |
| Dec 2025 | 2.8× | 8.70% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| BNTX BioNTech SE Sponsored ADR compare | 8.6× |
| INCY Incyte Corporation compare | 3.8× |
| EXEL Exelixis, Inc. compare | 3.2× |
| ASND Ascendis Pharma A/S compare | 3.0× |
| INSM Insmed, Inc. compare | 2.9× |
| ALNY Alnylam Pharmaceuticals, Inc. | 2.5× |
| BBIO BridgeBio Pharma, Inc. compare | 2.1× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement